Published: 9 November 2021
Author(s): Yugo Yamashita, Takeshi Morimoto, Takeshi Kimura
Issue: January 2022

Venous thromboembolism (VTE) is a common issue in patients with autoimmune diseases. One of the clinically relevant issues for VTE in autoimmune disorders is the optimal duration of anticoagulation therapy for the prevention of recurrent VTE. Currently, autoimmune disorders are thought to be a relatively strong risk factor for recurrent VTE, which leads to the recommendation of extended anticoagulation therapy of indefinite duration in the current VTE guidelines [1]. However, these considerations have been based on observational studies.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.